- Home
- ROIV vs FYBR Comparison
ROIV vs FYBR Comparison
Compare ROIV & FYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- FYBR
- Stock Information
- Founded
- ROIV 2014
- FYBR 1935
- Country
- ROIV United Kingdom
- FYBR United States
- Employees
- ROIV N/A
- FYBR N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- FYBR Telecommunications Equipment
- Sector
- ROIV Health Care
- FYBR Consumer Discretionary
- Exchange
- ROIV Nasdaq
- FYBR Nasdaq
- Market Cap
- ROIV 8.4B
- FYBR 9.0B
- IPO Year
- ROIV N/A
- FYBR N/A
- Fundamental
- Price
- ROIV $10.87
- FYBR $36.51
- Analyst Decision
- ROIV Buy
- FYBR Buy
- Analyst Count
- ROIV 4
- FYBR 9
- Target Price
- ROIV $17.50
- FYBR $35.33
- AVG Volume (30 Days)
- ROIV 6.2M
- FYBR 1.9M
- Earning Date
- ROIV 05-29-2025
- FYBR 04-29-2025
- Dividend Yield
- ROIV N/A
- FYBR N/A
- EPS Growth
- ROIV N/A
- FYBR N/A
- EPS
- ROIV N/A
- FYBR N/A
- Revenue
- ROIV $122,585,000.00
- FYBR $5,986,000,000.00
- Revenue This Year
- ROIV N/A
- FYBR $4.41
- Revenue Next Year
- ROIV N/A
- FYBR $2.92
- P/E Ratio
- ROIV N/A
- FYBR N/A
- Revenue Growth
- ROIV 140.04
- FYBR 3.69
- 52 Week Low
- ROIV $8.73
- FYBR $24.43
- 52 Week High
- ROIV $13.06
- FYBR $39.21
- Technical
- Relative Strength Index (RSI)
- ROIV 55.44
- FYBR 71.63
- Support Level
- ROIV $10.90
- FYBR $36.15
- Resistance Level
- ROIV $11.77
- FYBR $36.57
- Average True Range (ATR)
- ROIV 0.30
- FYBR 0.12
- MACD
- ROIV 0.01
- FYBR 0.03
- Stochastic Oscillator
- ROIV 56.60
- FYBR 95.37
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About FYBR Frontier Communications Parent Inc.
Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.